# CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

> **NCT06881537** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Locally Recurrent Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06881537
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06881537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06881537, "CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06881537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*